[ad_1]
It appears that Albert Burla, CEO of Pfizer, knows exactly where to eat the shoulder, as he did not wait for the completion of the necessary trials for the vaccine his company is developing in cooperation with German BioNTech to obtain the necessary approvals. to start manufacturing, to reap the rewards of one of the biggest deals expected. Vaccines, when the CEO of the American Pharmaceutical Company – which is closest to the promised vaccine against the “Corona” virus – planned to sell more than $ 5.5 million in Pfizer stock last Monday – it’s That is, the same day that the company announced without essential details that an experimental COVID-19 vaccine “has shown more than 90% effectiveness.”
This strong dose of hope was reflected positively in global markets, and in the Pfizer share price in particular, which reached its highest level in over a year at $ 41.99 that day. . Burla quickly sold more than 132,000 shares for $ 41.94 per share, just five cents below that high, according to Tuesday’s share deposit record.
The record shows that these shares represented more than 60% of Burla’s holdings in Pfizer shares. He still owns 78,273 shares directly, in addition to 3,539 others held indirectly by him, according to what was reported by the “New York Post” newspaper.
Records reveal that Burla – who previously earned more than $ 15 million in total direct compensation from Pfizer last year – was not the only company in the company to strike such a “timely deal” on Monday, vice-president. president and director of corporate affairs at headquarters. Manhattan’s Sally Sussman also sold more than 43,000 shares for $ 1.8 million, according to another filing.
Pfizer’s announcement on Monday inspired stock markets which rebounded in hopes the vaccine will help the global economy recover from the coronavirus pandemic. The Dow Jones Industrial Average rose 834 points to record its best day since June, while Pfizer stock closed 7.7% on Wednesday up to $ 39.20.
Source link
